Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373262 | 0.92 | ALDH1A1 (0.56) | HRH3ALDH1A1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL8485315 | 0.84 | ALDH1A1 (0.51) | HRH3ALDH1A1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL5206103 | 0.80 | OPRM1 (0.49) | L3MBTL1 | |
| SCHEMBL5206501 | 0.79 | OPRM1 (0.49) | MEN1KMT2A | |
| SCHEMBL5205363 | 0.77 | F2 (0.44) | HRH3MEN1KMT2A | |
| SCHEMBL4826474 | 0.76 | LMNA (0.51) | ALDH1A1L3MBTL1CYP2C9CYP2C19MAPK14 | |
| SCHEMBL5202187 | 0.75 | SLC2A1 (0.53) | ALDH1A1CYP2C9CYP2C19MAPK14HTR2B | |
| Benzene SCHEMBL1222682 | 0.75 | HPGD (0.36) | ALDH1A1MEN1GAAHTTKMT2A | |
| SCHEMBL5233388 | 0.75 | MEN1 (0.61) | HRH3ALDH1A1MEN1GAAHTT | |
| SCHEMBL3026559 | 0.74 | CYP2C9 (0.67) | HRH3ALDH1A1L3MBTL1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280374-B2 | Nanofluidic analytical devices and methods of using thereof | UNIVERSITY OF KANSAS (US) | 2025-04-22 | — | — | US | disclosed |
| US-10870881-B2 | Biomolecular processing platform and uses thereof | CORNELL UNIVERSITY (US) | 2020-12-22 | — | — | US | disclosed |
| EP-2954103-B1 | BIOMOLECULAR PROCESSING PLATFORM AND USES THEREOF | UNIV CORNELL (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180187257-A1 | BIOMOLECULAR PROCESSING PLATFORM AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-05 | — | — | US | disclosed |
| US-9909173-B2 | Biomolecular processing platform and uses thereof | CORNELL UNIVERSITY (US) | 2018-03-06 | — | — | US | disclosed |
| US-20150361489-A1 | BIOMOLECULAR PROCESSING PLATFORM AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-17 | — | — | US | disclosed |
| EP-2954103-A2 | BIOMOLECULAR PROCESSING PLATFORM AND USES THEREOF | Cornell University (US) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014124365-A2 | BIOMOLECULAR PROCESSING PLATFORM AND USES THEREOF | CORNELL UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20090306342-A1 | BINDING OF MOLECULES | BIO-LAYER PTY LIMITED (AU) | 2009-12-10 | — | — | US | disclosed |
| EP-1966603-A4 | BINDING OF MOLECULES | BIO LAYER PTY LTD (AU) | 2009-08-19 | — | — | EP | disclosed |
| EP-1966603-A1 | BINDING OF MOLECULES | Bio-Layer Pty Limited (AU) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007076580-A1 | BINDING OF MOLECULES | BIO-LAYER PTY LIMITED (AU) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306342-A1 | BINDING OF MOLECULES | CD2BP2, C1QBP, CD74 | HRH3 1725/4885ALDH1A1 1642/4885L3MBTL1 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.